The U.S. Food and Drug Administration granted fast-track status to Mereo BioPharma Group PLC's navicixizumab to treat ovarian cancer.
![]() |
London-based Mereo BioPharma is developing navicixizumab to treat high-grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least three prior therapies and/or before Roche Holding AG's Avastin.
The company added navicixizumab to its drug pipeline through the acquisition of oncology-focused biopharmaceutical company OncoMed Pharmaceuticals Inc.
Mereo BioPharma is evaluating navicixizumab, combined with chemotherapy drug paclitaxel, to treat patients with advanced heavily pretreated ovarian cancer in an ongoing phase 1b study.

